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ABSTRACT
DrugBank is a richly annotated resource that
combines detailed drug data with comprehensive
drug target and drug action information. Since its
first release in 2006, DrugBank has been widely used
to facilitate in silico drug target discovery, drug
design, drug docking or screening, drug metabolism
prediction, drug interaction prediction and general
pharmaceutical education. The latest version of
DrugBank (release 2.0) has been expanded signifi-
cantly over the previous release. With 4900 drug
entries, it now contains 60% more FDA-approved
small molecule and biotech drugs including 10%
more ‘experimental’ drugs. Significantly, more pro-
tein target data has also been added to the data-
base, with the latest version of DrugBank containing
three times as many non-redundant protein or drug
target sequences as before (1565 versus 524). Each
DrugCard entry now contains more than 100 data
fields with half of the information being devoted to
drug/chemical data and the other half devoted to
pharmacological, pharmacogenomic and molecular
biological data. A number of new data fields, includ-
ing food–drug interactions, drug–drug interactions
and experimental ADME data have been added in
response to numerous user requests. DrugBank has
also significantly improved the power and simplicity
of its structure query and text query searches.
DrugBank is available at http://www.drugbank.ca
INTRODUCTION
There are essentially two kinds of online drug
resources: (i) clinically oriented drug ‘encyclopedias’ and
(ii) chemically oriented drug databases. Examples of some
of the better clinically oriented drug resources include
PharmGKB (1) and RxList (2). These knowledgebases
tend to oﬀer very detailed clinical information about
selected drugs (their pharmacology, metabolism and
indications) with their data content being targeted more
towards pharmacists, physicians or consumers. Examples
of chemically oriented drug (or small molecule) databases
include the TTD (3), the Druggable Genome database (4),
KEGG (5), PubChem (6) and ChEBI (7). These excellent
databases provide synoptic data (5–10 data ﬁelds per
entry) about the nomenclature, structure and/or physical
properties of large numbers of small molecule drugs and,
in some cases, their drug targets. Chemically oriented drug
databases are typically oriented towards medicinal che-
mists, biochemists and molecular biologists. As a general
rule, chemically oriented drug databases aim for very
broad coverage at the expense of depth, while clinically
oriented drug resources aim for far more depth (albeit in
English sentences) at the expense of coverage.
In an eﬀort to bridge the ‘depth versus breadth’ gap
between clinically oriented drug resources and chemically
oriented drug databases, we developed DrugBank (8).
First released in 2006, DrugBank was designed to serve as
a comprehensive, fully searchable in silico drug resource
that linked sequence, structure and mechanistic data
about drug molecules (including biotech drugs) with
sequence, structure and mechanistic data about their
drug targets. As a clinically oriented drug encyclopedia,
DrugBank is able to provide detailed, up-to-date, quanti-
tative, analytic or molecular-scale information about
drugs, drug targets and the biological or physiological
consequences of drug actions. As a chemically oriented
drug database, DrugBank is able to provide many built-in
tools for viewing, sorting, searching and extracting text,
image, sequence or structure data. Since its initial release,
DrugBank has been used in a wide range of applications
including in silico drug discovery (9), drug ‘rejuvenation’
(10), drug docking or screening (11), drug metabolism
prediction (12), drug target prediction (13) and general
pharmaceutical education. Feedback from users has led
to many excellent suggestions on how to expand and
enhance DrugBank’s oﬀerings. These requests also led to
the development of several new software tools to improve
the entry, export and annotation of DrugBank’s data.
*To whom correspondence should be addressed. Tel: 780-492-0383; Fax: 780-492-1071; Email: david.wishart@ulberta.ca
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Here, we wish to report on these developments as well as
many additions and improvements appearing in the latest
version of DrugBank (release 2.0).
DATABASE ENHANCEMENTS
Details relating to DrugBank’s overall design, querying
capabilities, curation protocols, quality assurance and
drug selection criteria have been described previously (8).
These have largely remained the same between release 1.0
and 2.0. Here, we shall focus primarily on describing the
changes and enhancements made to the database and to
the annotation processes for release 2.0. More speciﬁcally,
we will describe the: (i) enhancements to the DrugBank’s
size and coverage; (ii) expanded database linkages;
(iii) data ﬁeld additions; (iv) improvements in data
querying and data viewing and (v) improvements to
DrugBank’s data handling processes.
Expandeddatabase size and coverage
A detailed content comparison between DrugBank
(release 1.0) versus DrugBank (release 2.0) is provided in
Table 1. As seen here, the latest release of DrugBank now
has detailed information on 1467 FDA-approved drugs
corresponding to 28447 brand names and synonyms. This
represents an expansion of nearly 60% over what was
previously contained in the database. The latest
DrugBank release also includes 123 biotech (peptide or
protein) drugs and 69 nutraceuticals (nutritional supple-
ments), which corresponds to an increase of 10% over
what was in the previous DrugBank release. While many
of these additions represent newly approved drugs (about
50 new drugs are approved each year), a number of these
new entries are little known, hard-to-ﬁnd or infrequently
prescribed drugs that are not contained in most drug
databases. To the best of our knowledge, DrugBank now
contains all (or almost all) drugs that have been approved
in North America, Europe and Asia. In addition,
DrugBank’s collection of experimental or unapproved
drugs (or drug-like) compounds, which is primarily
derived from the PDB’s Ligand database, has expanded
to include 3116 compounds, compared to 2896 com-
pounds in the ﬁrst release. We are pleased to note that
these experimental drugs have now been more completely
annotated, via BioSpider (14), than in the previous
DrugBank release.
In response to many user requests, we have also added
two new drug categories: (i) Withdrawn drugs and (ii)
Illicit drugs. Withdrawn drugs are those that have been
withdrawn from the market or certain market segments
due to safety concerns (such as Vioxx and Bextra). Illicit
drugs include those that are legally banned or selectively
banned in most developed nations (such as cocaine and
heroin). Chemical, pharmaceutical and biological infor-
mation about these classes of drugs is extremely impor-
tant, not only in understanding their adverse reactions,
but also in being able to predict whether a new drug entity
may have unexpected chemical or functional similarities to
a dangerous drug. The number of drugs in the
‘Withdrawn’ category is 57, while the number of drugs
in the ‘Illicit’ category is 188. As with all other entries in
DrugBank, the same level of drug, drug target and drug
action information has been collected for these drugs as
with all other drug entries in DrugBank. If one counts all
drug entries in DrugBank (FDA-approved, Experimental,
Biotech, Nutraceutical, Withdrawn, Illicit), the total
number of drugs or drug-like molecules comes to 4897,
which represents an increase by 25% over the previous
release.
A signiﬁcant increase in the number (and coverage) of
identiﬁed drug targets in DrugBank has been achieved for
this release of DrugBank, with 1565 non-redundant
protein/DNA targets being identiﬁed for FDA-approved
drugs compared to 524 non-redundant targets identiﬁed in
release 1.0. The identiﬁcation of so many more targets was
aided by PolySearch (http://wishart.biology.ualberta.ca/
polysearch/), a text-mining tool developed in our labora-
tory to facilitate these kinds of searches. Additional details
about PolySearch appear later in this article. All of these
newly identiﬁed protein targets are fully referenced to an
average of four PubMed citations each.
Of particular interest to many is DrugBank’s list of drug
targets. Several other drug target lists have been compiled
or presented including those in TTD (3), as well as others
by Hopkins et al. (15), Drews and Ryser (16), Imming
et al. (17) and Overington et al. (18). These report 578
molecular targets (out of 1512 total targets including
disease and organism targets), 248 protein targets (out of
399 molecular targets), 483 molecular targets, 218
molecular targets and 324 molecular targets, respectively.
DrugBank’s list of drug targets is 3–4 times larger than
these. The primary reasons are: (i) DrugBank has a much
larger collection of small molecule drugs (approximately
two times larger than any other resource), (ii) DrugBank
includes biotech drugs and nutraceuticals (which average
5–10 unique target proteins per drug), (iii) most other drug
target lists only include a single ‘primary’ target rather
than all targets that have been found to have physiological
or pharmaceutical eﬀects, (iv) DrugBank fully accounts
for the fact that many drug targets are protein complexes
Table 1. Comparison between the data content in DrugBank (release
1.0) versus DrugBank (release 2.0)
Category Release
1.0
Release
2.0
No. of FDA-approved small molecule drugs 841 1344
No. of biotech drugs 113 123
No. of nutraceutical drugs 61 69
No. of withdrawn drugs 0 57
No. of illicit drugs 0 188
No. of experimental drugs 2894 3116
No. of total Small molecule drugs 3796 4774
No. of total drugs 3909 4897
No. of names/brand names/synonyms 18304 28447
No. of data ﬁelds 88 108
No. of food–drug interactions 0 714
No. of drug–drug interactions 0 13242
No. of ADMET parameters (Caco-2, LogS) 0 276
No. of approved drug targets (non-redundant) 524 1565
No. of all drug targets (non-redundant) 2133 3037
No. of search types 8 12
D902 Nucleic Acids Research, 2008, Vol. 36, DatabaseissueFigure 1. A screenshot montage of some of DrugBank’s new or modiﬁed querying tools including ChemQuery, TextQuery and an example of the
new generic text query output.
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subunits and (v) DrugBank annotators identify molecules
as drug targets if they play a critical role in the transport,
delivery or activation of the drug.
As a general rule, when more than one drug target is
listed in DrugBank, the ordering of the drug targets
corresponds ‘approximately’ to their order of physiologi-
cal eﬀect or their importance regarding the drug’s
therapeutic indication(s).
Expandeddatabase linkages
DrugBank is a database that contains extensive links
to almost all major bioinformatics and biomedical
databases (GenBank, SwissProt/UniProt, PDB, ChEBI,
KEGG, PubChem and PubMed). It also contains many
links to numerous drug and pharmaceutical databases
(RxList, PharmGKB and FDA labels). Over the past year,
DrugBank has also been reciprocally linked by SwissProt/
UniProt, Wikipedia, BioMOBY (19) and PubChem
(October 2007). Because of DrugBank’s appeal as an
educational or public information resource, we are
actively seeking to expand these reciprocal linkages with
other databases and online resources. For example, all
drug entries in Wikipedia are now linked to DrugBank
and most drug ‘fact boxes’ in Wikipedia are actually
generated from DrugBank tables. For the latest release
of DrugBank, several new database links have been
added including hyperlinks to Wikipedia, PDRHealth,
the Drug Product Database (DPD), the Human Genome
Nomenclature Commission (HGNC), GeneCards (20) and
GeneAtlas (21).
Data fieldadditions
As seen in Table 1, DrugBank now contains 107 data
ﬁelds, compared to 88 data ﬁelds in release 1.0. Some
of these data ﬁelds have arisen to facilitate cataloging,
but most have been added in response to user needs
and user requests. Speciﬁcally, these new data ﬁelds
include: (i) a primary accession number; (ii) a secondary
accession number; (iii) drug synonyms; (iv) a compound
description; (v) drug brand names; (vi) SwissProt name
(if the drug is a peptide/protein drug); (vii) monoisotopic
molecular weight; (viii) isomeric SMILES string;
(ix) water solubility predicted via ALOGPS (22);
(x) LogP predicted via ALOGPS; (xi) CACO permeabil-
ity; (xii) experimental water solubility (LogS); (xiii) drug–
drug interactions; (xiv) food–drug interactions; (xv)
Human Protein Reference Database ID; (xvi) HGNC
ID; (xvii) GeneCards ID and (xviii) GeneAtlas ID. A total
of 194 experimental LogS values and 82 experimental
Caco-2 permeability values were obtained from the UCSD
ADME databases (23). These values, along with the
structural and physico-chemical data in DrugBank,
are particularly useful for computational ADMET
(Absorption, Distribution, Metabolism, Excretion and
Toxicty) prediction. Additionally, 714 food–drug interac-
tions and 13242 drug–drug interactions were compiled
(through a variety of web and textbook resources),
checked by an accredited pharmacist and entered
manually. As far as we are aware, these drug/drug and
food/drug compilations represent the most complete,
publicly accessible collection of its kind. This interac-
tion information is particularly useful for physicians,
pharmacists and patients. However, it is also of increasing
interest to those involved in pharmacogenomics and
nutrigenomics.
Enhanced queryingand viewing capabilities
A key feature that distinguishes DrugBank from other
online drug resources is its extensive support for higher
level database searching and selecting functions. In
addition to standard data viewing and sorting features,
DrugBank also oﬀers a generic text search, a local
BLAST search (SeqSearch), a higher level Boolean text
search (TextQuery), a chemical structure search utility
(ChemQuery) and a relational data extraction tool (Data
Extractor). Each of these search utilities has a number of
useful bioinformatics or cheminformatic applications,
many of which were described in the ﬁrst DrugBank
publication (8). For the latest release of DrugBank, we
have added a number of improvements to both the generic
text search and ChemQuery (Figure 1). In particular, the
generic text search has been enhanced so that users now
have the option of clicking on check boxes to limit their
search to either a drug’s common name, its synonyms/
brand names or all text ﬁelds. Because the vast majority of
queries to DrugBank are related to drug names/synonyms,
the default query always has these two boxes checked oﬀ.
Users wishing to search through the other 100+ data
ﬁelds in DrugBank can select the ‘all text ﬁelds’ box. This
change has also substantially improved the query response
times for most DrugBank text searches.
Because the spelling of many drug names, chemical
compound names and protein names is often diﬃcult or
non-intuitive, DrugBank now supports an ‘intelligent’ text
search, where alternative spellings to misspelled or
incompletely entered names are automatically provided.
In addition to this change, the results from text queries
have also been enhanced so that the standard tabular
output (primary accession number, generic drug name,
chemical formula and molecular weight) is supplemented
with the query word highlighted in the selected DrugCard
ﬁeld(s) from which it was retrieved.
To accommodate a variety of user requests and prefer-
ences, the ChemQuery tool has been modiﬁed for release
2.0 to allow two diﬀerent types of chemical drawing
applets to be used: the MarvinSketch (http://www.
chemaxon.com) structure drawing tool (new) and the
ACD structure drawing tool (old). The MarvinSketch
applet is somewhat more intuitive and easier to use, while
the ChemSketch (ACD) applet is somewhat more complex
but oﬀers more structural drawing options. The default
ChemQuery tool for this release is the MarvinSketch
applet. DrugBank’s structure querying capabilities have
also been enhanced with the addition of a ‘Show Similar
Structure(s)’ button located at the top of every DrugCard.
This allows users to rapidly search for structurally similar
small molecules, without having to redraw the molecule
and search the database through the ChemQuery inter-
face. Users can also limit their structure similarity search
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Nutracueticals, Illicit drugs, etc.) through a pull-down
menu located by the ‘Show Similar Structure(s)’ button.
Both ‘Show Similar Structures’ and ChemQuery use
a locally developed SMILES string comparison method
to identify related structures and to perform structure
similarity searches. All structures are converted to
SMILES strings and a substring-matching program
(similar to BLAST) is used to identify similar structures.
The scoring scheme is based simply on the number of
character matches for the longest matching substring.
Improved datahandling(entry, export andannotation)
For most of the past 5 years, DrugBank has existed as
a series of text ﬁles that were manually edited or ﬂat ﬁles
that were populated by writing Perl scripts to reformat
existing text to the DrugBank ﬁle format. Most of the
annotation in DrugBank (release 1.0) was assembled,
entered and validated manually. With the rapid growth in
the size and scope of DrugBank, along with the continuing
needs for updates, we have had to become far more
eﬃcient in our data management. Speciﬁcally, we have
had to streamline our methods for data entry, data export
and database annotation. However, we have continued to
maintain our same rigorous standards for manual data
validation.
To facilitate manual data entry and export for release
2.0, we have developed customized scientiﬁc data manage-
ment software (SDMS) called DrugBank–SDMS. This
web-enabled database system was built using the open
source Ruby-on-Rails web application framework. This
SDMS overlays a MySQL database that contains all of
the DrugBank data. The publicly viewable version of
DrugBank is directly linked to the DrugBank–SDMS such
that every night the SDMS data is automatically exported
to the DrugBank server. This ‘near synchrony’ between
the SDMS and DrugBank allows our database annotators
to remotely access the SDMS, to add data, to check
entries or to make corrections in real time, without the
need to write (or wait for) custom Perl scripts for data
uploads. The use of a SDMS also allows for more
extensive error checking. This is done both at the time of
entry (via automated format and spelling checks) and later
(once a week), through the use of ‘sanity checker’
(Supplementary Table 1) that checks the consistency of
chemical structure ﬁles, chemical formulae and chemical
properties using a variety of custom-built prediction and
ﬁle-formatting programs (8, 14, 24). The development of
a custom SDMS has also facilitated the export of publicly
downloadable DrugBank ﬁles. In particular, our SDMS
allows rapid generation of all of DrugBank’s ﬂat ﬁle (text)
downloads and facile creation of XML-formatted
DrugBank ﬁles—all of which are available through
DrugBank’s download link.
To improve our manual annotation eﬃciency and
coverage, the programming staﬀ at DrugBank has
developed several automated text and web-mining tools
including BioSpider (14) and PolySearch. BioSpider is a
web spider that automatically gathers biological, chemical
and pharmacological data from approximately 30 trusted,
content-rich web sites using only a compound name,
SMILES string or Chemical Abstract Service (CAS)
number as input. It then combines this data with a variety
of in-house molecular structure and property prediction
tools to generate data tables that corresponds to many of
the data ﬁelds in DrugBank. BioSpider allows many of the
tedious, error-prone or repetitive annotation activities in
DrugBank to be handled by a computer, allowing our
annotation team to concentrate on higher level annotation
tasks (such as, gathering data on pharmacology, mechan-
ism of action, metabolism or drug interactions). BioSpider
has been extensively evaluated (14) and has been found
to perform much better and much faster than skilled
human annotators in these low-level annotation tasks.
To complement BioSpider’s role in low-level annotation,
we have also developed PolySearch to enhance higher level
annotation and research. PolySearch is a text-mining tool
designed to mine data from abstracts in PubMed. It is
similar in concept and design to EBIMed (25) and
MedGene (26), but has been modiﬁed to facilitate the
extraction of informative sentences or infor-
mative abstracts related to drugs, drug targets, drug
metabolites, diseases, proteins and drug–protein interac-
tions. PolySearch is used as an adjunct to our manual
annotation eﬀorts and has greatly aided the identiﬁcation
of numerous or little-known drug targets.
All textual data acquired from the BioSpider and
PolySearch annotation programs are manually inspected
by a minimum of two individuals, with at least one
individual having an MD or a life science PhD. Additional
spot checks are routinely performed on each entry by
senior members of the curation group, including a
physician, an accredited pharmacist and two PhD-level
biochemists. While most information listed in the ‘Drug
Description’, ‘Pharmacology’, ‘Mechanisms of Action’,
‘Half Life’, ‘Biotransformation Data’, ‘Protein Binding’,
‘Toxicity’, ‘Absorption’ and ‘Indications’ data ﬁelds is
manually entered, those entries that are acquired from our
automated annotation tools are all manually veriﬁed and
edited (or rewritten) for readability and consistency. All
PolySearch-derived drug target data, in particular, has
been veriﬁed through multiple text sources (PubMed, drug
references, online sequence databases, online drug data-
bases and FDA labels) by at least two members of the
DrugBank curatorial staﬀ. Drugs with near-identical
structures and modes of action are cross-checked to
ensure that their drug target lists are nearly identical.
In addition to these manual checks, nearly 40 automated
data consistency checks are performed to ensure a
uniformly high level of data integrity (Supplementary
Table 1). Even with these added checks and references we
still recommend that users carefully study the data sources
prior to making decisions about using it.
FUTURE DIRECTIONS
The DrugBank model of ‘breadth + depth’ has served as
a good template for the development of other small
molecule databases in our laboratory, including the
Human Metabolome Database or HMDB (24) and
Nucleic Acids Research, 2008,Vol. 36,Database issue D905FooDB (http://hmdb.med.ualberta.ca/foodb). The lessons
learned from building these and other related ‘metabo-
lomic’ databases are also helping to generate ideas,
software and protocols that could signiﬁcantly enhance
the breadth and depth of information contained in future
releases of DrugBank. Over the coming 3 years,
DrugBank will adhere to a semi-annual updating schedule
with new updates being released on the January 1 and July
1 of each year. This will allow information on newly
approved and newly withdrawn drugs to be kept current.
Previous versions of the database will be available from
the DrugBank download page. A major focus over the
coming 2 years will be to extend the database’s querying
capabilities (improved structure searches), to acquire more
experimental spectral (MS and NMR) data, to expand its
coverage of nutraceuticals or herbal medicines, to enhance
the annotation of research/experimental compounds, to
add many more pathway or network diagrams and to add
a number of Java plug-ins to facilitate virtual drug
screening and pharmacological (ADMET) modeling.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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